REDWOOD CITY, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced that world renown cardiologist Dr. John Simpson will serve as Chair of its Scientific & Medical Alliance Board. Dr. Simpson is credited with inventing and commercializing the first over-the-wire balloon catheter used for percutaneous transluminal coronary angioplasty (PTCA). This single invention created the field of interventional cardiology as it is known today. He joins an already impressive roster of advisory board members who support Biotricity’s research and development with a focus on scientific and clinical excellence.
Over the course of his storied medical technology career, Dr. Simpson has founded and successfully exited companies like ACS and DVI (both acquired by Eli Lilly), CVIS (acquired by Boston Scientific), Perclose (sold to Abbott), Lumend (acquired by Cordis), and Fox Hollow (acquired by ev3 which is now part of Medtronic). Dr. Simpson received his PhD in Immunology from the University of Texas, his MD from Duke University, and completed his fellowship in interventional cardiology at Stanford University. He is a member of the American College of Physicians, a fellow of the American College of Cardiology, has published on a wide variety of medical subjects, and has lectured extensively throughout the world.
“It is with great pleasure that we announce Dr. John Simpson’s new position as Chair of our Scientific & Medical Alliance Board,” said Dr. Waqaas Al-Siddiq, Biotricity Founder and CEO. “Dr. Simpson’s extensive expertise in the medical technology sector will provide us with invaluable clinical insights and guidance as we continue to expand our product offerings.”
To learn more, visit www.biotricity.com or follow on:
Twitter: @biotricity_inc Facebook: facebook.com/biotricity/ or
LinkedIn: linkedin.com/company/biotricity-measuring-vitals
